OPRX Stock Overview
A digital health technology company, engages in the provision of tech-enabled marketing solutions for life sciences organizations, healthcare providers, and patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OptimizeRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.66 |
| 52 Week High | US$14.13 |
| 52 Week Low | US$3.78 |
| Beta | 1.18 |
| 1 Month Change | 0.23% |
| 3 Month Change | 58.03% |
| 1 Year Change | -13.40% |
| 3 Year Change | -69.74% |
| 5 Year Change | -6.68% |
| Change since IPO | -96.60% |
Recent News & Updates
A Subscription Model And EHR Network Will Reshape Healthcare
Apr 08 Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 06
Recent updates
A Subscription Model And EHR Network Will Reshape Healthcare
Apr 08 Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 06We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
Mar 08At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?
Feb 14Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
Dec 15Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
Nov 16OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)
Aug 24OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely
Aug 16Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?
May 31OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
Oct 12Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?
Sep 23OptimizeRx extends reach with Cooler Screens Partnership
Jul 26OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Jun 27Shareholder Returns
| OPRX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 3.3% | 7.5% | 7.0% |
| 1Y | -13.4% | 7.5% | 7.5% |
Return vs Industry: OPRX underperformed the US Healthcare Services industry which returned 8.4% over the past year.
Return vs Market: OPRX underperformed the US Market which returned 7.8% over the past year.
Price Volatility
| OPRX volatility | |
|---|---|
| OPRX Average Weekly Movement | 18.3% |
| Healthcare Services Industry Average Movement | 11.9% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: OPRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OPRX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 129 | Steve Silvestro | www.optimizerx.com |
OptimizeRx Corporation, a digital health technology company, engages in the provision of tech-enabled marketing solutions for life sciences organizations, healthcare providers, and patients. The company offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, HUB awareness, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. It also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms.
OptimizeRx Corporation Fundamentals Summary
| OPRX fundamental statistics | |
|---|---|
| Market cap | US$160.13m |
| Earnings (TTM) | -US$20.11m |
| Revenue (TTM) | US$92.13m |
1.7x
P/S Ratio-8.0x
P/E RatioIs OPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPRX income statement (TTM) | |
|---|---|
| Revenue | US$92.13m |
| Cost of Revenue | US$32.75m |
| Gross Profit | US$59.38m |
| Other Expenses | US$79.49m |
| Earnings | -US$20.11m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 12, 2025
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 64.45% |
| Net Profit Margin | -21.83% |
| Debt/Equity Ratio | 28.0% |
How did OPRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/28 04:51 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OptimizeRx Corporation is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Constantine Davides | Citizens JMP Securities, LLC |